EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

Kenneth J Moise iD, Leona E Ling, Dick Oepkes, Eleonor Tiblad, E J T Joanne Verweij, Enrico Lopriore, John Smoleniec, Ulrich J Sachs, Gregor Bein, Mark D Kilby iD, Russell S Miller, Roland Devlieger und 19 weitere

New England Journal of Medicine · 08.08.2024 · 391 (6) · 526-537

DOI: 10.1056/nejmoa2314466 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 08.08.2024. Verfasst von Kenneth J Moise und 30 weiteren Autor:innen. Beteiligte Einrichtung: From Dell Medical School, University of Texas at Austin, and the Comprehensive Fetal Care Center, Dell Children's Medical Center - both in Austin (K.…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Erythroblastosis, Fetal, Immunoglobulin G, Isoantibodies. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Janssen Research & Development, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedErythroblastosis, FetalImmunoglobulin GIsoantibodiesHydrops FetalisAdultFemaleHumansInfant, NewbornPregnancyBlood Transfusion, IntrauterineGestational AgeHistocompatibility Antigens Class ILive BirthReceptors, FcInfusions, IntravenousAnemia

Substanzen

Antibodies, Monoclonal, HumanizedFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GIsoantibodiesReceptors, Fc

Autor:innen und Institutionen

  • From Dell Medical School, University of Texas at Austin, and the Comprehensive Fetal Care Center, Dell Children's Medical Center - both in Austin (K.J.M.); Janssen Pharmaceuticals, Cambridge, MA (L.E.L., J.H.L., A.M., V…

ORCID-Profile: Kenneth J Moise, Mark D Kilby

Förderung

  • Janssen Research & Development, LLC

Zitieren

APA

Moise, K. J., Ling, L. E., Oepkes, D., Tiblad, E., Verweij, E. J. T. J., Lopriore, E., Smoleniec, J., Sachs, U. J., Bein, G., Kilby, M. D., Miller, R. S., Devlieger, R., Audibert, F., Emery, S. P., Markham, K., Norton, M. E., Ocón-Hernández, O., Pandya, P., Pereira, L., …, & UNITY Study Group (2024). Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn. New England Journal of Medicine, 391(6), 526-537. https://doi.org/10.1056/nejmoa2314466

Vancouver

Moise KJ, Ling LE, Oepkes D, Tiblad E, Verweij EJTJ, Lopriore E, et al. Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn. New England Journal of Medicine. 2024;391(6):526-537. doi:10.1056/nejmoa2314466

BibTeX
@article{Moise2024,
  author = {Moise, Kenneth J and Ling, Leona E and Oepkes, Dick and Tiblad, Eleonor and Verweij, E J T Joanne and Lopriore, Enrico and Smoleniec, John and Sachs, Ulrich J and Bein, Gregor and Kilby, Mark D and Miller, Russell S and Devlieger, Roland and Audibert, François and Emery, Stephen P and Markham, Kara and Norton, Mary E and Ocón-Hernández, Olga and Pandya, Pranav and Pereira, Leonardo and Silver, Robert M and Windrim, Rory and Streisand, James B and Leu, Jocelyn H and Mirza, Arpana and Smith, Valerie and Schwartz, Lisa B and Tjoa, May Lee and Saeed-Khawaja, Shumyla and Komatsu, Yosuke and Bussel, James B and UNITY Study Group, UNITY Study Group},
  title = {Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {6},
  pages = {526--537},
  doi = {10.1056/nejmoa2314466}
}
Kostenlos starten →